Novel neuromuscular blocking drugs and antagonists

Current Opinion in Anaesthesiology

Volumn 28, Issue 4, 2015, Pages 403-410

  Heerdt, Paul M ^a   Sunaga, Hiroshi ^b   Savarese, John J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

calabadion; CW002; gantacurium; isoquinolines; l cysteine; sugammadex

Indexed keywords

CALABADION; CW 002; CYSTEINE; GANTACURIUM; NEUROMUSCULAR BLOCKING AGENT; SUGAMMADEX; UNCLASSIFIED DRUG; GAMMA CYCLODEXTRIN DERIVATIVE; ISOQUINOLINE DERIVATIVE;

ANESTHESIA MECHANISM; CLINICAL PHARMACOLOGY; CLINICAL TRIAL (TOPIC); DRUG SCREENING; DRUG STRUCTURE; HISTAMINE RELEASE; HUMAN; IN VIVO STUDY; NEUROMUSCULAR BLOCKING; NONHUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW (TOPIC); UNSPECIFIED SIDE EFFECT; ANTAGONISTS AND INHIBITORS; PROCEDURES;

CYSTEINE; GAMMA-CYCLODEXTRINS; HUMANS; ISOQUINOLINES; NEUROMUSCULAR BLOCKADE; NEUROMUSCULAR NONDEPOLARIZING AGENTS;

EID: 84937938822     PISSN: 09527907     EISSN: 14736500     Source Type: Journal    
DOI: 10.1097/ACO.0000000000000209     Document Type: Review

References (45)

1. Marshall RJ, Muir AW, Sleigh T, Savage DS. Research and development of aminosteroid neuromuscular blocking agents: past and future. Eur J Anesthesiol 1995; 11:5-10.
2. Savarese JJ, Lien CA, Belmont MR, Rubin L. The clinical and basic pharmacology of mivacurium: a short-acting nondepolarizing benzylisoquinoliniumdiester neuromuscular blocking drug. Acta Anaesth Scand 1995; 39:18-22.
3. White PF. Rapacuronium: why did it fail as a replacement for succinylcholine Br J Anaesth 2002; 88:163-165.
4. Gyermek L. Development of ultra short-acting muscle relaxant agents: history, research strategies, and challenges. Med Res Rev 2005; 25:610-654.
5. Gyermek L, Lee C. The development of ultrashort acting neuromuscular relaxant tropane derivatives. J Crit Care 2009; 24:58-65.
6. Lien CA, Savard P, Belmont M, et al. Fumarates: unique nondepolarizing neuromuscular blocking agents that are antagonized by cysteine. J Crit Care 2009; 24:50-57.
7. Naguib M, Brull SJ. Update on neuromuscular pharmacology. Curr Opin Anaesthesiol 2009; 22:483-490.
8. Lien CA. Development and potential clinical impact of ultra-short-acting neuromuscular blocking agents. Br J Anaesth 2011; 107 (Suppl 1):i60-i71.
9. Samano V, Ray JA, Thompson JB, et al. Synthesis of ultra-short-acting neuromuscular blocker GW 0430: a remarkably stereo-and regioselective synthesis of mixed tetrahydroisoquinoliniumchlorofumarates. Org Lett 1999; 1:1993-1996.
10. Boros EE, Bigham EC, Boswell GE, et al. Bis-and mixed-tetrahydroisoquinoliniumchlorofumarates: new ultra-short-acting nondepolarizing neuromuscular blockers. J Med Chem 1999; 42:1114.
11. Kaldor I, Feldman PL, Mook RA Jr, et al. Stereocontrolled synthesis of cisdibenzoquinolizinechlorofumarates: curare-like agents of ultrashort duration. J Org Chem 2001; 66:3495-3501.
12. Boros EE, Samano V, Ray JA, et al. Neuromuscular blocking activity and therapeutic potential of mixed-tetrahydroisoquinoliniumhalofumarates and halosuccinates in rhesus monkeys. J Med Chem 2003; 46:2502-2515.
13. Savarese JJ, McGilvra JD, Sunaga H, et al. Rapid chemical antagonism of neuromuscular blockade by l-cysteine adduction to and inactivation of the olefinic (double-bonded) isoquinoliniumdiester compounds gantacurium(AV430A), CW002, and CW 011. Anesthesiology 2010; 113:58-73.
14. Savarese JJ, Belmont MR, Hashim MA, et al. Preclinical pharmacology of GW280430A(AV430A) in the rhesus monkey and in the cat: a comparison with mivacurium. Anesthesiology 2004; 100:835-845.
15. Heerdt PM, Kang R, The A, et al. Cardiopulmonary effects of the novel neuromuscular blocking drug GW280430A (AV430) in dogs. Anesthesiology 2004; 100:846-851.
16. Sunaga H, Zhang Y, Savarese JJ, et al. Gantacurium and CW002 do not potentiate muscarinic receptor-mediated airway smooth muscle constriction in Guinea pigs. Anesthesiology 2010; 112:892-899.
17. Belmont MR, Lien CA, Tjan J, et al. Clinical pharmacology of GW280430A in humans. Anesthesiology 2004; 100:768-773.
18. Heerdt PM, Malhotra JK, Pan BY, et al. Pharmacodynamics and cardiopulmonary side effects of CW002, a cysteine-reversible neuromuscular blocking drug in dogs. Anesthesiology 2010; 112:910-916.
19. Diaz LL, Zhang J, Heerdt PM. Comparative pharmacodynamics of pancuronium, cisatracurium, andCW002 in rabbits. J Am Assoc Lab Anim Sci 2014; 53:283-289.
20. Murrell MT, Malhotra JK, Sunaga H, et al. Potency and preliminary pharmacodynamics of the novel neuromuscular blocking drug CW002 in humans during sevoflurane/nitrous oxide anesthesia (ASA Abstracts 2013, LBB03).
21. Owens JS, Heerdt PM, Malhotra JK, et al. Pharmacokinetics of CW002, a novel neuromuscular blocking agent in the initial cohorts of a phase 1 clinical trial (AAPS Annual Meeting, 2014).
22. Savarese JJ, Belmont MR, Sunaga H, et al. Crossover studies in monkeys show that a new ultra-short acting nondepolarizer, CW 1759-50, in contrast with gantacurium, elicits no histaminoid phenomena (ASA Abstracts 2013, A2201.
23. Sunaga H, McGilvra J, Belmont MR, et al. CW1759-50: A new ultra-short acting nondepolarizer: Spontaneous recovery versus antagonism by L-cysteine (ASA Abstracts 2013, A4034).
24. Savarese JJ, Yi Zhang Y, Heerdt PM, Emala CW. The ultra-short acting neuromuscular blocker CW 1759-50 has approximately 5 times the safety of rapacurium at M2 and M3 receptor (ASA Abstracts 2014, A4003).
25. Savarese JJ, Sunaga H, Belmont MR, et al. The ultra-short acting neuromuscular blocker CW 1759-50 has very high autonomic safety in the isofluraneanesthetized cat (ASA Abstracts 2014, A4000).
26. Adam JM, Bennett DJ, Bom A, et al. Cyclodextrin-derived host molecules as reversal agents for the neuromuscular blocker rocuronium bromide: synthesis and structure-activity relationships. J Med Chem 2002; 45:1806-1816.
27. Ledowski T. Sugammadex. What do we know and what do we still need to know A review of the recent (2013 to 2014) literature. Anaesth Intensive Care 2015; 43:14-22.
28. Abrishami A, Ho J, Wong J, et al. Cochrane corner: sugammadex, a selective reversal medication for preventing postoperative residual neuromuscular blockade. AnesthAnalg 2010; 110:1239.
29. Schepens T, Cammu G. Neuromuscular blockade: what was, is and will be. Acta Anaesthesiol 2014; 65:151-159.
30. Farhan H, Moreno-Duarte I, McLean D, Eikermann M. Residual paralysis: does it influence outcome after ambulatory surgery Curr Anesthesiol Rep 2014; 4:290-302.
31. Hoffmann U, Grosse-Sundrup M, Eikermann-Haerter K, et al. Calabadion: a new agent to reverse the effects of benzylisoquinoline and steroidal neuromuscular-blocking agents. Anesthesiology 2013; 119:317-325.
32. Ma D, Zhang B, Hoffmann U, et al. Acyclic cucurbit[n]uril-type molecular containers bind neuromuscular blocking agents in vitro and reverse neuromuscular block in vivo. Angew Chem Int Ed Engl 2012; 51:11358-11362.
33. Macartney DH. Cucurbit[n]uril type hosts for the reversal of steroidal neuromuscular blocking agents. Future Med Chem 2013; 5:2075-2089.
34. Isaacs L. Stimuli responsive systems constructed using cucurbit[n]uril-type molecular containers. Acc Chem Res 2014; 47:2052-2062.
35. Wang Y, Li D, Wang H, et al. pH responsive supramolecular prodrug micelles based on cucurbit[8]uril for intracellular drug delivery. Chem Commun (Camb) 2014; 50:9390-9392.
36. Zlotkin SH, Bryan MH, Anderson GH. Cysteine supplementation to cysteinefree intravenous feeding regimens in newborn infants. Am J ClinNutr 1981; 34:914-923.
37. Zuin R, Palamidese A, Negrin R, et al. High-dose n-acetylcysteine in patients with exacerbations of chronic obstructive pulmonary disease. Clin Drug Investig 2005; 25:401-408.
38. Schaller G, Pleiner J, Mittermayer F, et al. Effects of N-acetylcysteine against systemic and renal hemodynamic effects of endotoxin in healthy humans. Crit Care Med 2007; 35:1869-1875.
39. Kortsalioudaki C, Taylor RM, Cheeseman P, et al. Safety and efficacy of Nacetylcysteine in children with nonacetaminophen-induced acute liver failure. Liver Transpl 2008; 14:25-30.
40. Karila L, Gorelick D, Weinstein A, et al. New treatments for cocaine dependence: a focused review. Int J Neuropsychopharmacol 2008; 11:425-438.
41. Ng F, Berk M, Dean O, Bush AI. Oxidative stress in psychiatric disorders: evidence base and therapeutic implications. Int J Neuropsychopharmacol 2008; 11:851-876.
42. Sunaga H, Malhotra JK, Yoon E, et al. Cysteine reversal of the novel neuromuscular blocking drugCW002 in dogs: pharmacodynamics, acute cardiovascular effects, and preliminary toxicology. Anesthesiology 2010; 112:900-909.
43. Sharpe LG, Olney JW, Ohlendorf C, et al. Brain damage and associated behavioral deficits following the administration of l-cysteine to infant rats. Pharmacol Biochem Behav 1975; 3:291-298.
44. Sawamoto O, Hagiwara R, Kurisu K. L-cysteine-induced brain damage in adult rats. Exp Toxicol Pathol 2004; 56:45-52.
45. Janaky R, Varga V, Hermann A, et al. Mechanisms of l-cysteine neurotoxicity. Neurochem Res 2000; 25:1397-1405.